Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.50 -2.6%	$3.31	$2.70 ▼ $4.72	$669.99M	0.86	863,984 shs	342,948 shs
DERM Journey Medical	$7.39 -1.1%	$7.16	$3.54 ▼ $8.90	$172.67M	0.8	110,324 shs	77,366 shs
FBIO Fortress Biotech	$2.28 +0.4%	$1.92	$1.33 ▼ $2.36	$67.84M	1.76	274,857 shs	451,987 shs
KALV KalVista Pharmaceuticals	$13.01 -3.0%	$13.40	$7.30 ▼ $16.32	$649.80M	0.05	780,502 shs	347,973 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	0.00%	+6.53%	+11.49%	+11.49%	-7.71%
DERM Journey Medical	0.00%	+7.48%	-1.58%	+6.71%	+54.66%
FBIO Fortress Biotech	0.00%	+7.08%	+15.23%	+27.53%	+8.61%
KALV KalVista Pharmaceuticals	0.00%	+4.11%	-8.02%	+16.91%	+6.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	2.6976 of 5 stars	3.5	1.0	0.0	3.4	2.5	0.6
DERM Journey Medical	1.7103 of 5 stars	3.3	1.0	0.0	2.5	0.8	0.6
FBIO Fortress Biotech	2.8327 of 5 stars	3.5	1.0	0.0	3.0	3.3	0.6
KALV KalVista Pharmaceuticals	4.0036 of 5 stars	3.6	1.0	4.4	2.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	57.37% Upside
DERM Journey Medical	2.50	Moderate Buy	$12.17	64.64% Upside
FBIO Fortress Biotech	3.00	Buy	$16.50	623.68% Upside
KALV KalVista Pharmaceuticals	3.11	Buy	$26.29	102.07% Upside

Current Analyst Ratings Breakdown

Latest DERM, FBIO, ABUS, and KALV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2025	DERM Journey Medical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$13.00
8/21/2025	FBIO Fortress Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $17.00
8/15/2025	DERM Journey Medical	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/13/2025	DERM Journey Medical	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $13.00
8/11/2025	ABUS Arbutus Biopharma	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/8/2025	KALV KalVista Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$19.00 ➝ $27.00
7/8/2025	KALV KalVista Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $27.00
7/7/2025	KALV KalVista Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$18.00 ➝ $20.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$15.42M	43.46	N/A	N/A	$0.51 per share	6.85
DERM Journey Medical	$56.40M	3.05	N/A	N/A	$0.91 per share	8.12
FBIO Fortress Biotech	$59.30M	1.14	N/A	N/A	($0.06) per share	-38.00
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$1.92 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$69.92M	-$0.29	N/A	N/A	N/A	-352.24%	-59.28%	-44.11%	11/5/2025 (Estimated)
DERM Journey Medical	-$14.67M	-$0.38	N/A	N/A	N/A	-15.49%	-48.69%	-11.26%	11/11/2025 (Estimated)
FBIO Fortress Biotech	-$46M	-$1.05	N/A	N/A	N/A	-24.84%	-301.81%	-27.48%	11/13/2025 (Estimated)
KALV KalVista Pharmaceuticals	-$183.44M	-$3.69	N/A	N/A	N/A	N/A	-134.07%	-82.65%	9/4/2025 (Estimated)

Latest DERM, FBIO, ABUS, and KALV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/4/2025	Q1 2026	KALV KalVista Pharmaceuticals	-$0.91	N/A	N/A	N/A	$1.97 million	N/A
8/14/2025	Q2 2025	FBIO Fortress Biotech	-$0.31	-$0.46	-$0.15	$0.45	$14.53 million	$16.41 million
8/12/2025	Q2 2025	DERM Journey Medical	-$0.07	-$0.16	-$0.09	-$0.16	$14.93 million	$15.01 million
8/6/2025	Q2 2025	ABUS Arbutus Biopharma	-$0.02	$0.01	+$0.03	$0.01	$2.21 million	$10.74 million
7/10/2025	Q4 2025	KALV KalVista Pharmaceuticals	-$0.83	-$3.69	-$2.86	-$0.99	$4.20 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
DERM Journey Medical	N/A	N/A	N/A	N/A	N/A
FBIO Fortress Biotech	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	20.53	20.53
DERM Journey Medical	1.11	1.27	0.95
FBIO Fortress Biotech	1.34	1.92	1.70
KALV KalVista Pharmaceuticals	N/A	5.35	5.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
DERM Journey Medical	7.25%
FBIO Fortress Biotech	96.51%
KALV KalVista Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	20.30%
DERM Journey Medical	15.03%
FBIO Fortress Biotech	27.90%
KALV KalVista Pharmaceuticals	10.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	191.70 million	152.78 million	Optionable
DERM Journey Medical	90	23.30 million	20.71 million	N/A
FBIO Fortress Biotech	170	29.76 million	21.45 million	Optionable
KALV KalVista Pharmaceuticals	100	49.95 million	48.18 million	Optionable

DERM, FBIO, ABUS, and KALV Headlines

Recent News About These Companies

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Consensus Recommendation of "Buy" from Brokerages

August 20, 2025 | marketbeat.com

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Average Rating of "Buy" by Brokerages

August 19, 2025 | americanbankingnews.com

KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Up 3.7% - Time to Buy?

August 16, 2025 | marketbeat.com

Stocks To Watch: KalVista Pharmaceuticals Sees Relative Strength Rating Rise To 82

August 15, 2025 | msn.com

KalVista Pharmaceuticals (NASDAQ:KALV) Share Price Crosses Below 50-Day Moving Average - Time to Sell?

August 14, 2025 | marketbeat.com

Stocks With Rising Relative Strength: KalVista Pharmaceuticals

August 12, 2025 | msn.com

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

August 11, 2025 | globenewswire.com

KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union

August 11, 2025 | finance.yahoo.com

Kaken strengthens late-stage HAE portfolio with $32M deal for rights to Astria’s navenibart in Japan

August 7, 2025 | fiercebiotech.comF

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 4, 2025 | businesswire.com

EMA Backs First Oral Treatment for Hereditary Angioedema

July 29, 2025 | medscape.comM

KalVista Pharmaceuticals (KALV) Received Positive Opinion From the European Medicines Agency

July 29, 2025 | msn.com

KalVista Pharmaceuticals Ekterly Faces A Shrinking Market And Oral Competitor Threat (Downgrade)

July 27, 2025 | seekingalpha.com

KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Down 6.5% - Here's Why

July 26, 2025 | marketbeat.com

KALV - KalVista Pharmaceuticals Inc Key Metrics - Morningstar

July 25, 2025 | morningstar.comM

New medicines recommended for approval by EMA’s CHMP

July 25, 2025 | thepharmaletter.comT

KalVista Gets CHMP Backing for Ekterly in Hereditary Angioedema

July 25, 2025 | marketwatch.com

KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Crosses Above Fifty Day Moving Average - What's Next?

July 25, 2025 | marketbeat.com

KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks

July 25, 2025 | businesswire.com

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Average Recommendation of "Buy" by Brokerages

July 25, 2025 | marketbeat.com

KalVista Pharmaceuticals receives UK MKRA marketing authorization for sebetralstat to treat hereditary angioedema attacks

July 18, 2025 | pharmabiz.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

DERM, FBIO, ABUS, and KALV Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.50 -0.10 (-2.65%)

Closing price 03:59 PM Eastern

Extended Trading

$3.50 +0.01 (+0.29%)

As of 04:04 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Journey Medical NASDAQ:DERM

$7.39 -0.08 (-1.07%)

Closing price 03:59 PM Eastern

Extended Trading

$7.39 0.00 (0.00%)

As of 04:04 PM Eastern

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Fortress Biotech NASDAQ:FBIO

$2.28 +0.01 (+0.44%)

Closing price 03:58 PM Eastern

Extended Trading

$2.28 0.00 (-0.22%)

As of 04:04 PM Eastern

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

KalVista Pharmaceuticals NASDAQ:KALV

$13.01 -0.40 (-3.00%)

Closing price 03:59 PM Eastern

Extended Trading

$12.99 -0.02 (-0.14%)

As of 04:04 PM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time